New hope for those suffering from Dupuytren’s disease, an incurable and disabling hand condition

IMAGE: PROFESSOR JAGDEEP NANCHAHAL EXAMINES PATIENT WITH DUPUYTREN’S DISEASE. view more
CREDIT: NDORMS
Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren’s disease.

Based on their laboratory data that tumour necrosis factor (TNF) drives the development of myofibroblasts, the cell type that causes Dupuytren’s disease, the research team explored the effect of an anti-TNF drug injected directly into the Dupuytren’s nodule tissue. The results so far are very promising.

“Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren’s disease,” said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.

“This brings new hope to people who suffer from this disabling condition, who currently have to wait for their situation to be deteriorate, watching their hand lose function until it is bad enough for surgery. And then there’s the lengthy recovery ahead, a less than ideal situation to find yourself in.”

This randomised trial (phase 2a) recruited 28 patients with Dupuytren’s disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand. Two weeks prior to surgery they received a single injection of varying doses of the anti-TNF drug, or placebo. The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory. The team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells. They also found the drug to be safe and well tolerated.

The findings are published on line in the journal EBioMedicine, published by The Lancet.

Dupuytren’s disease is a common condition of the hand that affects 4% of the UK population and causes the fingers to curl irreversibly into the palm. There is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.

The anti-TNF drug adalimumab (Humira) is currently licensed in the EU for the treatment of a number of conditions including rheumatoid arthritis, Crohn’s disease and ulcerative colitis and overall has an excellent safety profile.

“We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren’s disease,” said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute. In conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.

“The Kennedy Institute has a long history of successfully translating laboratory findings to the clinic'” said Professor Fiona Powrie, Director of the Institute. “This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years”.

The researchers are continuing to investigate the use of this drug to treat Dupuytren’s disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.

Learn more: New hope for patients with incurable and disabling hand condition, Dupuytren’s disease

 

 

The Latest on: Dupuytren’s disease

[google_news title=”” keyword=”Dupuytren’s disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

via Google News

 

The Latest on: Dupuytren’s disease
  • Heart Disease News
    on May 22, 2024 at 5:00 pm

    In total, over 2,000 independent ... Cardio-Fitness Cuts Death and Disease by Nearly 20% Apr. 29, 2024 — Groundbreaking new research finds that an increased cardio fitness level will reduce your ...

  • DWP: Warning as 1.1m Brits with common pain problem could get £737 cash boost
    on May 15, 2024 at 11:12 pm

    New DWP figures also revealed that there are now 3.5 million people across England, Scotland, and Wales claiming PIP. These payments can range from £28.70 to £184.30 each week, and as the benefit is ...

  • What's worse for disease spread: animal loss, climate change or urbanization?
    on May 15, 2024 at 9:08 am

    Human-caused climate change can push disease-carrying mosquitoes or ticks into new places as temperatures rise, and deforestation can expose humans to viruses circulating in once-isolated species.

  • What to know about Raynaud's disease
    on May 9, 2024 at 4:59 pm

    Raynaud’s disease is an issue with blood circulation that causes the fingers or toes to turn white or pale and then blue, cold, and numb. It occurs when temperatures drop and blood vessels spasm ...

  • Imagine living in a 4-foot body that doesn’t develop chronic diseases
    on April 30, 2024 at 8:34 am

    “I am also quite lucky because in reality my body protects me a lot from diseases that other people have every day,” she added. “This height, at the same time as being a limitation, is also ...

  • America’s Infectious-Disease Barometer Is Off
    on April 29, 2024 at 5:00 pm

    “It’s almost like having the opportunity to catch COVID-19 in the fall of 2019,” Nahid Bhadelia, the founding director of Boston University Center on Emerging Infectious Diseases, told m ...

  • Can rock climbing lead to Dupuytren’s disease?
    on April 24, 2024 at 4:33 pm

    Objectives: To determine if rock climbing is a significant factor in the development of Dupuytren’s disease in men, and, if so, what is the most likely related factor. Methods: Questionnaires were ...

  • Crohn’s Disease Versus Ulcerative Colitis: What’s the Difference?
    on November 13, 2023 at 11:34 am

    “The most basic difference is that Crohn’s disease can involve the entire GI tract, from the mouth all the way down to the anus, whereas ulcerative colitis is restricted to the colon,” says ...

  • Heart Disease: Facts, Statistics, and You
    on July 19, 2023 at 5:00 pm

    Heart disease is the number one cause of death worldwide, regardless of gender and race. Here are some important facts to know about heart disease and other heart-related conditions. Illustration ...

via  Bing News

 

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top